Hematologic and cardiovascular outcomes of SGLT2 inhibitors in patients with chronic lymphocytic leukemia and type 2 diabetes: A real-world TriNetX analysis.
Retrospective cohort study examines SGLT2i impact on cardiovascular and hematologic outcomes in CLL and diabetes, suggesting benefits.
Key Points
This research aims to evaluate the effects of SGLT2 inhibitors on hematologic and cardiovascular outcomes in patients with chronic lymphocytic leukemia and type 2 diabetes.
Conducted a retrospective cohort study using the TriNetX Analytics Network.
Compared outcomes between SGLT2-exposed and non-exposed cohorts for infectious complications, hematologic outcomes, and mortality.
Employed propensity score matching to minimize confounding effects.
SGLT2 inhibitor use correlated with a lower pneumonia risk (HR 0.70, 95% CI 0.56-0.89) and reduced cardiovascular mortality (13.9% vs 21.9%; HR 0.70, 95% CI 0.59-0.83).
Observed a numerical reduction in all-cause mortality but no significant difference (HR 0.91, 95% CI 0.76-1.10).
SGLT2i users showed lower thrombocytopenia risk and similar rates of autoimmune hemolytic anemia, indicating selective benefits.